|
ORF cDNA clones
|
CRISPR / TALEN
|
Lentivirus
|
AAV
|
TALE-TF
|
ORF knockin clones
|
|
Antibody
|
Proteins
|
miRNA target clones
|
qPCR primers
|
shRNA clones
|
miRNA products
|
Promoter clones
|
Validated All-in-One™ qPCR Primer for PROX1(NM_002763.4) Search again
Product ID:
HQP055546
(click here to view gene annotation page)
Powered by BiozSpecies:
Human
Symbol:
Alias:
-
Gene Description:
prospero homeobox 1
Target Gene Accession:
NM_002763.4(click here to view gene page)
Estimated Delivery:
Approximately 1-3 weeks, but may vary. Please email sales@genecopoeia.com or call 301-762-0888 to confirm ETA.
Important Note:
By default, qPCR primer pairs are designed to measure the expression level of the splice variant (accession number) you selected for this gene WITHOUT consideration of other possible variants of this gene. If this gene has multiple variants, and you would like to measure the expression levels of one particular variant, multiple variants, or all variants, please contact us for a custom service project at inquiry@genecopoeia.com.
Validated result:
|
|
| A | B |
|
Each All-in-One™ qPCR Primer is experimentally validated to yield a single dissociation curve peak and to generate a single amplification of the correct size for the targeted gene. A cDNA Pool, containing reverse transcript products of 8 different human tissue total RNA(Liver, Testis,Muscle,Thyroid,Brain,Spleen,Stomach,Small Intestine)),was used as the qPCR validation template. qPCR was performed using 0.2 µM primer with 2XAll-in-One™ qPCR Mix (Catalog#: QP001,QP002,QP004,QP005). Reactions were incubated for 10min. at 95°C, followed by 40 cycles of 95°C for 10 sec.; 60°C, 20 sec. and 72°C, 15sec. using Bio-Rad iQ5™ Instrument. At the end of the last cycle, temperature was increased from 72 to 95°C to produce a melting curve. Panel A: Validated Result for Amplification Curve; Panel B: Validated Result for Melting Curve. |
|
Gene References into function
- Prox 1 is expressed in both quiescent and proliferating lymphatic endothelial cells in the adult human and mouse liver. Unlike the putative lymphatic marker LYVE-1, Prox 1 is not expressed in liver sinusoidal endothelial cells.
- Prox 1 is expressed in both quiescent and proliferating lymphatic endothelial cells in the liver. Unlike the putative lymphatic marker LYVE-1, Prox 1 is not expressed in liver sinusoidal endothelial cells.
- PROX1 is a marker of lymphatic endothelial cells in the lymphatics of human fetuses.
- Prox1 is differentially localized during lens development
- Prox-1 acts as a cell proliferation inducer and a fate determination factor for lymphatic endothelial cells.
- lymphatic vasculature originated from the blood vasculature by the additional expression of only a few gene products such as Prox1.
- Prox1 activity is both necessary and sufficient for progenitor-cell proliferation and cell-fate determination in the vertebrate retina.
- PROX1 gene corresponds to that of a candidate tumor-suppressor gene.
- The homeodomain protein Prox1 was characterized as a co-repressor for liver receptor homologue 1 (LRH1/NR5A2).
- The suppression by Prox1 on the transcriptional activity of liver receptor homolog-1 can be mediated through its interaction with the ligand binding domain of LRH-1.
- Prox1 is a highly conserved transcription factor, expressed in hepatocytes from the earliest stages of development into adulthood and over-expressed in hepatoma cell lines.
- CD 31/Prox-1 double-immunolabeling can be used as an adjunct marker to identify lymphatic vessels in routinely processed formalin-fixed, paraffin-embedded samples.
- Prox1 is a novel co-regulator of HNF4alpha that may play a key role in the regulation of bile acid synthesis and gluconeogenesis in the liver
- Prox1 was significantly reduced in pancreatic cancer specimens from patients with short survival rates, and loss of Prox1 function may be a driving force behind pancreatic carcinoma progression.
- Prox1 is involved in the differentiation and progression of hepatoma, and may be a candidate for the development of novel diagnostic and therapeutic strategies.
- mechanisms like genomic deletions and hypermethylation, which are prototypic for the inactivation of tumor suppressor genes, inactivate PROX1 in carcinomas of the bilary system
- RNA mutation of the prox1 gene plays a pivotal role in the pathogenesis of human cancer progression.
- we have identified PROX1 as a novel target gene that is hypermethylated and transcriptionally silenced in primary and metastatic breast cancer.
- analysis of prox1 RNA mutations detected in human esophageal cancer cells by the shifted termination assay
- interaction of CEACAM1 with Prox1 and VEGFR-3 plays a crucial role in tumor lymphangiogenesis and reprogramming of vascular endothelial cells to lymphatic endothelial cells
- Altered Prox1 mRNA expression is partly regulated by MAZ, and mutation of the prospero domain in hepatocellular carcinoma indicates an involvement for Prox1 during tumor progression.
- In intestinal tumors PROX1 is a direct and dose-dependent target of the beta-catenin/TCF signaling pathway, responsible for the neoplastic transformation.
- Prox1 plays an important, previously unanticipated role in mediating the aggressive behavior of vascular neoplasms such as Kaposi's sarcoma
- These findings suggest that sumoylation may serve as a novel mechanism for the regulation of Prox1's corepressor activity.
- These findings establish Prox1 as a new negative regulator of IFN-gamma expression in T cells .